Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia.
Roberts, Thomas Uwenedi, Grace Bruton, Rachel McIlroy, Graham Damery, Sarah Sylla, Panagiota Logan, Nicola Scott, Sam Lau, May Elzaidi, Ahmed
Roberts, Thomas
Uwenedi, Grace
Bruton, Rachel
McIlroy, Graham
Damery, Sarah
Sylla, Panagiota
Logan, Nicola
Scott, Sam
Lau, May
Elzaidi, Ahmed
Abstract
Cancer patients who are immune suppressed remain at increased risk from COVID-19 and have recently been prioritised for additional booster bivalent vaccines. Despite this, previous studies have shown that humoral and cellular immune responses often fail to reach levels comparable to the general population following booster doses. The emergence of the omicron variant of SARS-CoV-2 has necessitated the deployment of modified bivalent mRNA vaccines that direct the synthesis of spike protein from Omicron in combination with ancestral spike. Bivalent booster vaccines have shown utility in general population studies [1,2,3] but there is little understanding of their relative immunogenicity in patients with immune suppression.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2024-01-25
Type
Article
Subject
Collections
Citation
Roberts T, Uwenedi G, Bruton R, McIlroy G, Damery S, Sylla P, Logan N, Scott S, Lau M, Elzaidi A, Plass S, Mallick S, Spencer K, Stephens C, Bentley C, Pratt G, Zuo J, Paneesha S, Willett B, Moss P, Parry H. Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2024 Jan 25;14(1):22. doi: 10.1038/s41408-023-00940-5. PMID: 38272915; PMCID: PMC10810811.